CBS 2019
CBSMD教育中心
English

双重抗血小板治疗持续时间

科研文章

荐读文献

Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy after Implantation of Drug-eluting Stents Guided by either Intravascular Ultrasound or Angiography in Patients with Acute Coronary Syndrome: Rationale and Design of Prospective, Multicenter, Randomized, Controlled IVUS-ACS & ULTIMATE-DAPT trial Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry 'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction Long-term dual antiplatelet-induced intestinal injury resulting in translocation of intestinal bacteria into blood circulation increased the incidence of adverse events after PCI in patients with coronary artery disease

Clinical Trial2020 Nov 12;S0140-6736(20)32236-4.

JOURNAL:Lancet. Article Link

Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial

J Silvain, B Lattuca, ALPHEUS investigators et al. Keywords: ticagrelor vs. clopidogrel; periprocedural myocardial necrosis; stable coronary artery disease; aspirin and clopidogrel; intravenous cangrelor;

Full Text PDF